Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending September 27, 2015
Carfilzomib in Multiple Myeloma, Associating dosage with response
Second Malignancies in CTCL, Which neoplasms have highest incidence?
Lenalidomide in Myelodysplastic Syndromes, Does rash warrant discontinuation?
High-count Monoclonal B-cell Lymphocytosis, Assessing the risk of non-hematologic cancer
ASCO Endorses Small-Cell Lung Cancer Guidelines, Updates 2013 Guidelines
Must reads for theWeek ending September 20, 2015
Multiple Myeloma in Vietnam War Veterans, Associating Agent Orange with MGUS
Social Factors in AML , Do they increase mortality risk?
Overall Survival in Newly Diagnosed Multiple Myeloma, Studying which factors decrease risk
Factor VIII Inhibitors in Hemophilia A, Screening for high-titer and low-titer inhibitors
FDA Approves Varubi , Prevents nausea and vomiting from chemotherapy
Must reads for theWeek ending September 13, 2015
Promacta Expands Indication, Lowers age threshold and adds formulation
Deferasirox Therapy in MDS, Studying its effect on mortality
Treatment of Chemotherapy-associated Anemia, Which marrow-stimulating regimen performs best?
Second Malignancies in CLL, Evaluating the effects of acute leukemias and MDS
Oral Mucositis Treatment With Palifermin, Comparing its safety vs placebo
Must reads for theWeek ending September 6, 2015
Dasatinib in Acute Lymphoblastic Leukemia, Is it efficacious in the long term?
Outcomes in FLT3 ITD Mutated AML, Tracking trends over the past 15 years
Subtypes of Acute Myeloid Leukemia, Assessing the prognostic power of subtypes
Coffee Intake in CRC, How does it influence recurrence and mortality?
Therapies in Resected Pancreatic Adenocarcinoma, Comparing chemo alone and with radiotherapy
Must reads for theWeek ending August 30, 2015
Sprycel Labeling Change Approved, Now lists expanded efficacy and safety data
Adcetris Approved for Hodgkin Lymphoma, Indicated for high-risk patients
Elotuzumab in Multiple Myeloma, Studied with lenalidomide and dexamethasone
Karotypic Abnormalities in CMML, What can they predict?
Mortality in Acute Promylelocytic Leukemia, Which factors have prognostic value?